294 related articles for article (PubMed ID: 34392614)
1. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract][Full Text] [Related]
2. ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
Kumar S; Wilkes DW; Samuel N; Blanco MA; Nayak A; Alicea-Torres K; Gluck C; Sinha S; Gabrilovich D; Chakrabarti R
J Clin Invest; 2018 Nov; 128(11):5095-5109. PubMed ID: 30295647
[TBL] [Abstract][Full Text] [Related]
3. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
4. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.
Liu W; Zhan Z; Zhang M; Sun B; Shi Q; Luo F; Zhang M; Zhang W; Hou Y; Xiao X; Li Y; Feng H
Theranostics; 2021; 11(13):6278-6292. PubMed ID: 33995658
[No Abstract] [Full Text] [Related]
5. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells.
Vito A; Salem O; El-Sayes N; MacFawn IP; Portillo AL; Milne K; Harrington D; Ashkar AA; Wan Y; Workenhe ST; Nelson BH; Bruno TC; Mossman KL
Commun Biol; 2021 Jul; 4(1):859. PubMed ID: 34253827
[TBL] [Abstract][Full Text] [Related]
7. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
[TBL] [Abstract][Full Text] [Related]
8. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
9. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2022 Jan; 9(3):e2105793. PubMed ID: 35075800
[No Abstract] [Full Text] [Related]
10. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
Dominguez C; McCampbell KK; David JM; Palena C
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093275
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
16. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
18. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
19. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
20. Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer.
Senapati P; Kato H; Lee M; Leung A; Thai C; Sanchez A; Gallagher EJ; LeRoith D; Seewaldt VL; Ann DK; Schones DE
Epigenetics Chromatin; 2019 Jul; 12(1):44. PubMed ID: 31315653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]